EWP
CRSP icon

Engrave Wealth Partners’s CRISPR Therapeutics CRSP Stock Holding History

Engrave Wealth Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-30
Closed -$2K – 136
2020
Q2 		$2K Buy
+30
New +$1.75K ﹤0.01% 390

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Engrave Wealth Partners's CRSP Position: Q3 2020 in Review

Engrave Wealth Partners sold out of CRISPR Therapeutics (CRSP) in Q3 2020, closing a stake of 30 shares — an estimated $2K sold.

Engrave Wealth Partners first reported a position in CRSP in Q2 2020 and held it in 1 quarter. The position peaked at $2K in Q2 2020. 310 funds tracked by Wall St. Rank hold CRSP as of Q3 2020.

  • Engrave Wealth Partners reported no remaining CRISPR Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Engrave Wealth Partners sold 30 CRISPR Therapeutics shares in Q3 2020, an estimated $2K.
  • Engrave Wealth Partners first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 1 quarter.
  • Engrave Wealth Partners's CRISPR Therapeutics position peaked at $2K in Q2 2020.
  • 310 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2020.

Based on Engrave Wealth Partners's 13F filing for Q3 2020, filed 8 Oct 2020.